SCHEMBL6168992

SCHEMBL6168992

CCOC(=O)c1cccc(NC(C)=O)c1[N+](=O)[O-]

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.62
ALDH1A1 P00352 6/20 0.61
LMNA P02545 3/20 0.61
HPGD P15428 2/20 0.61
POLB P06746 2/20 0.61
NPSR1 Q6W5P4 2/20 0.61
GALR2 O43603 1/20 0.61
MITF O75030 1/20 0.61
HSP90AA1 P07900 1/20 0.61
XBP1 P17861 1/20 0.61
CCR6 P51684 1/20 0.61
KMT2A Q03164 2/20 0.55
MAPK1 P28482 2/20 0.54
MAPT P10636 2/20 0.54
MEN1 O00255 1/20 0.54
TSHR P16473 2/20 0.47
GAA P10253 2/20 0.47
KDM4E B2RXH2 5/20 0.47
HSD17B10 Q99714 2/20 0.47
CYP1A2 P05177 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13705663 0.86 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1LMNAHPGDPOLB
SCHEMBL9793680 0.82 POLB (0.50) SMN1; SMN2ALDH1A1HPGDPOLBNPSR1
SCHEMBL2656516 0.82 POLB (0.50) SMN1; SMN2ALDH1A1HPGDPOLBNPSR1
SCHEMBL20395326 0.81 HSD17B10 (0.51) SMN1; SMN2ALDH1A1HPGDPOLBNPSR1
SCHEMBL6656676 0.80 MEN1 (0.68) SMN1; SMN2ALDH1A1LMNAHPGDPOLB
SCHEMBL18285205 0.80 TSHR (0.56) SMN1; SMN2ALDH1A1LMNAHPGDPOLB
SCHEMBL7312805 0.80 LMNA (0.71) SMN1; SMN2ALDH1A1LMNAHPGDNPSR1
SCHEMBL16407064 0.79 HSD17B10 (0.61) SMN1; SMN2ALDH1A1LMNAHPGDPOLB
SCHEMBL3789796 0.79 ALDH1A1 (0.64) SMN1; SMN2ALDH1A1HPGDPOLBKMT2A
SCHEMBL27507150 0.79 ALDH1A1 (0.61) SMN1; SMN2ALDH1A1LMNAHPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882718-B1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-08-31 EP disclosed
US-6352985-B1 CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-05 US disclosed
US-6166219-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 US disclosed
EP-0882718-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-09 EP disclosed